These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 2237407)
1. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Fikrig E; Barthold SW; Kantor FS; Flavell RA Science; 1990 Oct; 250(4980):553-6. PubMed ID: 2237407 [TBL] [Abstract][Full Text] [Related]
2. Protection of mice from Lyme borreliosis by oral vaccination with Escherichia coli expressing OspA. Fikrig E; Barthold SW; Kantor FS; Flavell RA J Infect Dis; 1991 Dec; 164(6):1224-7. PubMed ID: 1955724 [TBL] [Abstract][Full Text] [Related]
3. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. Luke CJ; Carner K; Liang X; Barbour AG J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201 [TBL] [Abstract][Full Text] [Related]
4. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Probert WS; LeFebvre RB Infect Immun; 1994 May; 62(5):1920-6. PubMed ID: 8168958 [TBL] [Abstract][Full Text] [Related]
5. Borrelia burgdorferi strain 25015: characterization of outer surface protein A and vaccination against infection. Fikrig E; Barthold SW; Persing DH; Sun X; Kantor FS; Flavell RA J Immunol; 1992 Apr; 148(7):2256-60. PubMed ID: 1545130 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody. Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491 [TBL] [Abstract][Full Text] [Related]
7. Lyme borreliosis in transgenic mice tolerant to Borrelia burgdorferi OspA or B. Fikrig E; Tao H; Chen M; Barthold SW; Flavell RA J Clin Invest; 1995 Oct; 96(4):1706-14. PubMed ID: 7560061 [TBL] [Abstract][Full Text] [Related]
8. Long-term protection of mice from Lyme disease by vaccination with OspA. Fikrig E; Barthold SW; Kantor FS; Flavell RA Infect Immun; 1992 Mar; 60(3):773-7. PubMed ID: 1541551 [TBL] [Abstract][Full Text] [Related]
9. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi. Luke CJ; Huebner RC; Kasmiersky V; Barbour AG Vaccine; 1997; 15(6-7):739-46. PubMed ID: 9178476 [TBL] [Abstract][Full Text] [Related]
10. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi. Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011 [TBL] [Abstract][Full Text] [Related]
11. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis. Dunne M; al-Ramadi BK; Barthold SW; Flavell RA; Fikrig E Infect Immun; 1995 Apr; 63(4):1611-4. PubMed ID: 7890431 [TBL] [Abstract][Full Text] [Related]
12. Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC. Zhong W; Gern L; Stehle T; Museteanu C; Kramer M; Wallich R; Simon MM Eur J Immunol; 1999 Mar; 29(3):946-57. PubMed ID: 10092099 [TBL] [Abstract][Full Text] [Related]
13. Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview. Sadziene A; Barbour AG Infection; 1996; 24(2):195-202. PubMed ID: 8740122 [TBL] [Abstract][Full Text] [Related]